genetic deafness Archives | DelveInsight Business Research

Tag: genetic deafness

transthyretin amyloidosis

NOTIZIA

Jan 2, 2018• Business Consultant, Notizia, Oncology based Indications, Pharma Consultant, Uncategorized

Announcement of the new logo: Introducing a new brand identity, and a new website.

Business Consultant, Pharma Consultant
Thyroid eye disease market: New therapies enter the TED market

Articles, Business Consultant, Pharma Consultant
Tepezza receives approval; a new way to treat Alzheimer’s; and a new anti-obesity molecule

Business Consultant, Pharma Consultant, Pharma news
Polypills: Can they offer a potential approach to treat CVDs?

Business Consultant, Pharma Consultant, Snippets
Imfinzi combo gets ODD; Mayzent gets EU nod; Positive results of VP-102

Business Consultant, News, Pharma Consultant
In a blind race to cure HIV, can Gene therapy be a deal-breaker?

Articles, Business Consultant, DelveInsight's Drug Report, DelveInsight's Indication Pipeline Reports, Pharma Consultant
Glaucoma therapeutics market: Present therapies and unmet needs

Articles, Business Consultant, DelveInsight's Drug Report, DelveInsight's Indication Pipeline Reports, Pharma Consultant
Thumbs down to NKTR-181, Lilly expands its insulin armamentarium, 23andMe out-licences its drug

Business Consultant, Pharma Consultant, Pharma news
Malignant Pleural Mesothelioma Upcoming Therapies

Business Consultant, DelveInsight's Drug Report, DelveInsight's Indication Pipeline Reports, DelveInsight's Oncology based Reports, Pharma Consultant, Snippets
Eli Lilly to acquire Dermira, Boehringer buys Enleofen’s IL-11 platform, Biogen acquires Pfizer’s Alzheimer’s drug

Business Consultant, News, Pharma Consultant, Pharma news